Researchers sought to determine whether a novel variant of activated human factor VII Marzeptacog alfa (activated) would be effective as prophylactic treatment in patients with severe congenital hemophilia with inhibitors.
Researchers sought to determine whether rFVIII Fc-fusion protein would be a cost-effective treatment option for patients with severe hemophilia A.
Researchers sought to determine whether antithrombin would have the potential to restore thrombin generation in patients with hemophilia A.
Researchers sought to determine whether clearer guidelines are needed for utilizing ultrasounds to assess musculoskeletal outcomes in patients with hemophilia.
Researchers sought to determine whether combined training would improve lipid profiles and quality of life in patients with hemophilia A who were overweight.
People with hemophilia tend to have less adherence to prophylaxis as they transition to adulthood but continuing the therapy can improve their joint health.
Researchers sought to determine whether plasma-derived von Willebrand factor/factor VIII would be safe and effective in patients with hemophilia A younger than 12 years.
Researchers sought to determine the impact of the COVID-19 lockdown on patients with hemophilia.
Researchers sought to determine whether patients with hemophilia could safely perform moderate intensity training without adverse effects.
Researchers sought to determine whether emicizumab would help improve outcomes for patients with acquired hemophilia A.
